Firefly Neuroscience (AIFF) and Its Peers Head to Head Review

Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) is one of 93 public companies in the “Healthcare Technology” industry, but how does it compare to its competitors? We will compare Firefly Neuroscience to related companies based on the strength of its institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and risk.

Analyst Recommendations

This is a summary of recent ratings and price targets for Firefly Neuroscience and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Firefly Neuroscience 1 0 0 0 1.00
Firefly Neuroscience Competitors 455 1539 2761 89 2.51

As a group, “Healthcare Technology” companies have a potential upside of 48.61%. Given Firefly Neuroscience’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Firefly Neuroscience has less favorable growth aspects than its competitors.

Profitability

This table compares Firefly Neuroscience and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Firefly Neuroscience -386.15% -71.97% -59.30%
Firefly Neuroscience Competitors -750.24% -29.42% -15.32%

Earnings & Valuation

This table compares Firefly Neuroscience and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Firefly Neuroscience $1.14 million -$19.88 million -2.02
Firefly Neuroscience Competitors $341.86 million -$24.15 million 12.22

Firefly Neuroscience’s competitors have higher revenue, but lower earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Firefly Neuroscience has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Firefly Neuroscience’s competitors have a beta of 1.11, meaning that their average stock price is 11% more volatile than the S&P 500.

Institutional & Insider Ownership

5.0% of Firefly Neuroscience shares are owned by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Firefly Neuroscience competitors beat Firefly Neuroscience on 11 of the 13 factors compared.

Firefly Neuroscience Company Profile

(Get Free Report)

Firefly Neuroscience is a medical technology company developing tools to assess brain function and support care for neurological and mental health conditions. Its Brain Network Analytics (BNA) platform analyzes electroencephalogram (EEG) data and compares results with a proprietary database to provide clinicians with information about patients’ brain activity. The company’s technology is intended to help clinicians evaluate conditions such as depression, attention-deficit/hyperactivity disorder, dementia and concussion, and to inform assessment and treatment decisions.

Receive News & Ratings for Firefly Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firefly Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.